Exciting news! NLS Pharmaceutics secures exclusive global license for Aexon’s Dual Orexin Receptor Agonists platform, advancing treatments for narcolepsy, hypersomnia, and neurodegenerative disorders. Stay tuned for updates! Full article: rb.gy/1vva0x $NLSP

NLS issued 7M shares at $0.25/share, raising $1.75M with H.C. Wainwright & Co. as exclusive placement agent. Funds to advance innovative CNS disorder therapies. Full article: rb.gy/c4vew3 #nlspharmaceutics $NLSP

To Safeguard and Empower the Brain throughout all Stages of Life. We're dedicated to protecting and empowering the brain. #NLSPharmaceutics #HealthyBrain #Narcolepsy $NLSP

Exciting News! NLS Pharmaceutics announces promising preclinical results for KO-874 at ASCP in Miami! Potential new treatment for sleep disorders! Read the full article here: rb.gy/zqgykj #NLSPharmaceutics #ASCP2024 $NLSP

Our CSO, Dr. Eric Konofal, MD, PhD, will unveil groundbreaking research on Mazindol´s neuroprotective effects in a narcoleptic rat model at the ASCP annual meeting in Miami today! Join us from 12:30-2:15pm ET. Poster available here: rb.gy/yv1pt0 #nlspharmaceutics $NLSP

Exciting news! We´ve partnered with Aexon Labs to introduce a new patent for dual orexin receptor agonists. These innovative, non-sulfonamide compounds could revolutionize treatments for narcolepsy and Parkinson´s. Full article: rb.gy/g9e468 #nlspharmaceutics $NLSP

NLS Pharmaceutics has been granted an extension by the Nasdaq Hearings Panel until October 14, 2024, to meet continued listing requirements. This allows us time to strengthen our financial position. Full article: rb.gy/rpdsaj #nlspharmaceutics #narcolepsy $NLSP

NLS Pharmaceutics (NASDAQ: NLSP) and Kadimastem (KDST.TA) are merging! Kadimastem shareholders to hold 85% New entity to trade on Nasdaq as Kadimastem NLS’s DOXA platform continues Read the full article here: rb.gy/wnw14a #nlspharmaceutics $NLSP

NLS Pharmaceutics (Nasdaq: NLSP) announces 1-for-40 reverse share split effective Sept 27, 2024. Shares will trade under the same symbol “NLSP” but with a new CUSIP. Full article: rb.gy/mgkk8e #nlspharmaceutics #narcolepsy $NLSP

Big news from NLS Pharmaceutics! We raised $3.2M in a private placement and settled $4M in debt. Plus, we believe we’ve regained Nasdaq compliance! Full article: rb.gy/8qqfjr #nlspharmaceutics #narcolepsy $NLSP

👏 Kudos to Kadimastem LTD and iTolerance ! They completed a pre-IND meeting with the U.S. FDA, bringing us closer to a potential cure for Type 1 Diabetes. Exciting times ahead for our future combined company!nasdaq.com/press-release/…

NLS Pharmaceutics announces new preclinical data for AEX-2, our groundbreaking dual orexin receptor agonist! 🧠✨ AEX-2 enhances wakefulness & reduces cataplexy—transforming sleep disorder treatments! #innovationquotes feeds.issuerdirect.com/news-release.h…

NLS has announced the closing of up to $2M equity financing and a $25M equity facility agreement! These financial resources will support our merger with Kadimastem LTD and the advancement of clinical trials for transformative therapies in ALS and diabetes. Exciting times ahead!

Exciting news! NLS' KO-943 study shows Mazindol reduces fentanyl-induced reward in animal models! As we prepare for our merger with Kadimastem LTD, Mazindol remains a key focus for future strategic partnerships in addiction treatment. #AddictionResearch #addiction #biotech

At American Society of Clinical Pschopharm (ASCP) NLS Pharmaceutics will present preclinical results showing Mazindol ER reduces both fentanyl reward and withdrawal symptoms in animal models. A promising non-opioid approach to fighting addiction. 📍Poster #KO-943 | May 29 #CNS #PharmaNews #OpioidCrisis

CEO Issues Letter to shareholders: NLS has raised $6M+, cleared all debt, and advanced key clinical programs. The Kadimastem merger is on track as we prepare for ALS and diabetes trials. 🧾 finance.yahoo.com/news/nls-pharm… #Biotech #ALS #Diabetes #CNS

We’ve closed the final $1M of our $3M financing! This supports our merger with Kadimastem and advances programs in ALS and diabetes. Kadimastem LTD #biotech #regenerativemedicine finance.yahoo.com/news/nls-pharm…

🚨 Patent milestone: Our merger partner Kadimastem LTD secures IP protection in Hong Kong for its IsletRx #diabetes program—expanding global coverage after Europe, U.S. & India. Hong Kong = key Asia hub + gateway to China. finance.yahoo.com/news/nls-pharm…